Last reviewed · How we verify

Wockhardt — Portfolio Competitive Intelligence Brief

Wockhardt pipeline: 3 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 0 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cefepime 2000 mg Cefepime 2000 mg marketed
Novolin 70/30 Novolin 70/30 marketed Insulin combination (intermediate-acting and short-acting) Insulin receptor Diabetes
Novolin N Novolin N marketed Intermediate-acting insulin Insulin receptor Diabetes
Intravenous Levonadifloxacin/Linezolid Infusion Intravenous Levonadifloxacin/Linezolid Infusion phase 3 Fluoroquinolone/Oxazolidinone combination antibiotic Bacterial DNA gyrase, topoisomerase IV, 50S ribosomal subunit Infectious Disease
Oral Levonadifloxacin/Linezolid Tablet Oral Levonadifloxacin/Linezolid Tablet phase 3 Fluoroquinolone/Oxazolidinone combination antibiotic DNA gyrase, topoisomerase IV, 50S ribosomal subunit Infectious Disease
Cefepime-zidebactam (FEP-ZID) Cefepime-zidebactam (FEP-ZID) phase 3 Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Charles Drew University of Medicine and Science · 1 shared drug class
  3. Eli Lilly and Company · 1 shared drug class
  4. Geropharm · 1 shared drug class
  5. Ivan Šitum, MD · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. National University of Singapore · 1 shared drug class
  8. Novo Nordisk A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Wockhardt:

Cite this brief

Drug Landscape (2026). Wockhardt — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wockhardt. Accessed 2026-05-14.

Related